CLINICAL TRIAL: KLH WITH GM-CSF, IN PATIENTS WITH FOLLICULAR NON-HODGKIN'S LYMPH

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这是一项随机、双盲、第三阶段的研究，旨在评估这种特定免疫疗法与非特异性免疫疗法在滤泡性非霍奇金淋巴瘤(NHL)患者中的安全性和有效性。研究赞助商Genitope依靠重组分子生物学技术生产独特型疫苗。这项研究将确定GTOP-99(独特型蛋白与载体蛋白KLH结合的化合物，称为GTOP-99)是否具有延长缓解的效果。对副作用的观察与相关的第二阶段疫苗研究一致。疫苗耐受性良好，注射部位有红斑、硬结和轻微疼痛，这些都是最常见的副作用。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a randomized, double-blind, Phase III study to evaluate the safety and efficacy of this specific immunotherapy, compared to non-specific immunotherapy in patients with follicular non-Hodgkin's Lymphoma (NHL). Genitope, the study sponsor, relies on recombinant molecular biological techniques to produce the idiotype vaccine. The study will determine if GTOP-99 (the compound of idiotype protein bound to the carrier protein KLH is know as GTOP-99) has efficacy in prolonging remission. Observations of the side effects have been consistent with relevant Phase II vaccine studies. The vaccines have been well tolerated, with erythema, induration, and mild pain at the injection sites, the most commonly reported side effects.